SHARE

News Alert: Citius Pharmaceuticals Receives FDA Approval For LYMPHIR™ (Denileukin Diftitox-Cxdl) Immunotherapy For The Treatment Of Adults With Relapsed Or Refractory Cutaneous T-Cell Lymphoma. Click to Read More.

Growblox Sciences Inc (OTCMKTS:GBLX) has announced the launch of its new corporate website. As per the new website, the company has three operating divisions. These include GB Sciences, GB Solutions and GB Products. Additionally, Lazarus Management Co LLC, has filed to purchase 22.3% of Growblox shares. The move reflects Lazarus’s confidence in the growing cannabis company.

Growblox focuses on technologies associated with plant biology and cultivation, with a special concentration on the cannabis market. The company’s cultivation suite is currently being commercialized by its Puerto Rico wing. It is hoped that the suite will be used by global cannabis growers and other plant based medical solution providers. The CEO of Growblox, Craig Ellens, stated that his company has gone through a lot of hurdles to get a clear vision and understanding of the cannabis industry. He also stated that the new website is targeted at getting the resulting message to the consumers and other businesses.

Each of the three divisions of the company serves a specific purpose.

  • GB Sciences: takes care of regulatory compliances, drug trials, product claims and new product developments. Additionally, the division collaborates with academic partners in order to produce a product pipeline of cannabinoid based therapies.
  • GB Solutions: oversees the supply chain and logistics operations. It is also responsible for engineering and industrial design systems validation. Additionally, the division is currently focusing on the commercialization of the company’s technology suite.
  • GB Products: is the only division that has not started operations yet, but is expected to do so by end of 3Q2015. The division will look at the product design, distribution and marketing of the therapies.

Growblox also focuses on manufacturing safe and standardized cannabis based therapies, which treat a number of medical conditions. The company also works on large data driven clinical researches.

Growblox Sciences Inc (OTCMKTS:GBLX) closed at $0.551, after losing 5% on May 14. The company has 34.9 million shares in the market, with a 52-week range of $0.15-$3.49.